

Date: 29-01-2020

To
Mr. BhushanMokashi
Manager
Bombay Stock Exchange Limited,
PhirozeJeeJeebhoy Towers,
Dalal Street, MUMBAI – 400 001.

Sir,

Sub: Outcome of the Board Meeting – Reg.D
Ref: Our Company code no: 532041.

The following is the Outcome of the Board Meeting of the Company held on 29th January, 2020 at 02.00 P.M. at the registered office of the Company:


- 1 The Board has approved the un-audited financial results of the company for the quarter ended on 31st December, 2019.

We are herewith enclosing un-audited financial results of the company & Limited Review Report certified by the auditor for the quarter ended 31.12.2019, as per Clause 33 (3) of SEBI (LODR) Regulations, 2015.

This is for your information and record.

Thanking you

Yours faithfully,
For **Hindustan Bio Sciences Limited**


J Varun Varma
Director



HINDUSTAN BIO SCIENCES LIMITED

Plot No.31, Sagar Society, Road No.2, Banjara Hills, Hyderabad 500 034

Phone No. 23555161, Fax 40205171

STATEMENT OF UN AUDITED RESULTS FOR THE QUARTER /NINE MONTHS ENDED 31st DECEMBER,2019

(Rs. In Lakhs)

Sl. No.	Particulars	Quarter ended			Nine Months Ended		Year ended
		31.12.2019 (Unaudited)	30.09.2019 (Unaudited)	31.12.2018 (Unaudited)	31.12.2019 (Unaudited)	31.12.2018 (Unaudited)	31.03.2019 (audited)
1	Income from Operations						
	(a) Revenue from operations	38.20	13.95	107.03	109.67	313.29	356.34
	(b) Other Income	0	-	-	-	-	0.06
	Total Revenue (1)	38.20	13.95	107.03	109.67	313.29	356.40
2	Expenses						
	(a) cost of material consumed	-	-	-	-	-	-
	(b) Purchases of Stock -in-trade	12.53	6.43	73.95	68.53	269.21	292.13
	(c) Changes in Inventories of finished goods,Stock - in-Trade and Work-in-Progress	12.66	9.39	6.86	2.98	(9.31)	(3.45)
	(d) Employee Benefit Expenses	6.24	6.30	6.16	18.88	16.16	22.41
	(e) Finance Costs	0.16	0.30	0.40	0.63	0.75	1.04
	(f) Selling Expenses	0.21	0.15	0.75	0.45	1.22	1.63
	(g) Depreciation and amortisation Expenses	0.30	0.32	0.25	0.90	0.78	1.07
	h) Other Expenses	4.64	5.29	11.15	16.17	24.83	30.34
	Total Expenses(2)	36.74	28.18	99.52	108.54	303.63	345.17
3	Profit/(Loss) before Exceptional& Extraordinary items and tax (1 -2)	1.46	(14.23)	7.51	1.13	9.66	11.23
4	Exceptional items	-	-	-	-	-	-
5	Profit/(Loss) before tax(3 -4)	1.46	(14.23)	7.51	1.13	9.66	11.23
6	Tax Expenses						
	(a) Current Tax	-	-	-	-	-	-
	(b) Deferred Tax	-	-	-	-	-	(0.23)
7	Profit /(Loss) for the period from continuing operations(5-6)	1.46	(14.23)	7.51	1.13	9.66	11.00
8	Profit /(Loss) from discontinued operations	-	-	-	-	-	-
9	Tax Expense of discontinued operations	-	-	-	-	-	-
10	Profit /Loss from Discontinued operations after tax(8-9)	-	-	-	-	-	-
11	Profit/(Loss) for the period(7+10)	1.46	(14.23)	7.51	1.13	9.66	11.00
12	Other Comprehensive Income						
	A (1) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(2) Income tax relating to items that will not be re- classified to profit or loss	-	-	-	-	-	-
	B (1) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(2) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
13	Total Comprehensive Income for the period (11+12) (comprising Profit (Loss) and other comprehensive income for the period	1.46	(14.23)	7.51	1.13	9.66	11.00
14	Paid up Equity Capital(Face value of Rs. 10/- each)	1,025.08	1,025.08	1,025.08	1,025.08	1,025.08	1,025.08
15	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year						(808.72)
16	Earnings per equity share for continuing operations						
	(A) Basic	0.01	(0.14)	0.07	0.01	0.09	0.11
	(B) Diluted	0.01	(0.14)	0.07	0.01	0.09	0.11
17	Earnings per equity share for discontinuing operations						
	(A) Basic	-	-	-	-	-	-
	(B) Diluted	-	-	-	-	-	-
18	Earnings per equity share(for discontinuing & continuing operations						
	(A) Basic	0.01	(0.14)	0.07	0.01	0.09	0.11
	(B) Diluted	0.01	(0.14)	0.07	0.01	0.09	0.11

Notes:

- 1 The Unaudited Financial Results were taken on record by the Board of Directors in their meeting held on 29.01.2020.
- 2 Previous year figures have been regrouped wherever necessary.

Place: Hyderabad
Date: 29.01.2020

For Hindustan Bio Sciences Limited

J.Varun Varma
Director





INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

**Review Report to
The Board of Directors of
Hindustan Biosciences Limited**

We have reviewed the accompanying statement of unaudited financial results of **Hindustan Biosciences Limited** for the period ended 31st December 2019. This statement is the responsibility of the company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the statement in accordance with the standard on review Engagements (SRE) 2410 "Review of Interim Financial Information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and provide less assurance than audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**Place : Hyderabad
Date : January, 29, 2020**

**For C.RAMACHANDRAM & CO.,
Chartered Accountants**



C.RAMACHANDRAM
Partner

Membership no.025834

UDIN : 20025834AAAACS5817